Sanofi accuses MSD of US patent infringement
pharmafile | September 19, 2016 | News story | Sales and Marketing | MSD, Sanofi, lawsuit
Sanofi has filed a suit against MSD in the United States District Court for the District of Delaware accusing the US firm of infringing ten of its patents.
This move comes after a notification that MSD has filed a New Drug Application with the FDA for an insulin glargine drug product; the company asserts that its NDA included a paragraph IV certification challenging all of the ten patents listed in the FDA Orange Book for Sanofi’s Lantus and Lantus SoloStar products.
Matt Fellows
Related Content
Merck shares data from phase 3 trial of Keytruda for gastric cancers
Merck, known as MSD outside of the US and Canada, has announced data from the …
Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia
Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib …
Sanofi shares phase 2b results for dermatitis treatment
Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …